LU87210A1 - Nouvelle composition ophtalmologique - Google Patents
Nouvelle composition ophtalmologique Download PDFInfo
- Publication number
- LU87210A1 LU87210A1 LU87210A LU87210A LU87210A1 LU 87210 A1 LU87210 A1 LU 87210A1 LU 87210 A LU87210 A LU 87210A LU 87210 A LU87210 A LU 87210A LU 87210 A1 LU87210 A1 LU 87210A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- acid
- corneal
- cellulose
- ophthalmological composition
- days
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 18
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 13
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 13
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229920013820 alkyl cellulose Polymers 0.000 claims description 4
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 150000004665 fatty acids Chemical class 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 210000004087 cornea Anatomy 0.000 description 10
- 206010011033 Corneal oedema Diseases 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 201000004778 corneal edema Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 208000006069 Corneal Opacity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 239000004165 Methyl ester of fatty acids Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000018931 inflamed eyes Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8710780 | 1987-05-07 | ||
| GB878710780A GB8710780D0 (en) | 1987-05-07 | 1987-05-07 | Opthalmological application of eicosapentaenoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU87210A1 true LU87210A1 (fr) | 1988-12-13 |
Family
ID=10616936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU87210A LU87210A1 (fr) | 1987-05-07 | 1988-05-06 | Nouvelle composition ophtalmologique |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4897421A (en]) |
| JP (1) | JPS63297323A (en]) |
| KR (1) | KR880013557A (en]) |
| AU (1) | AU1567888A (en]) |
| BE (1) | BE1001075A3 (en]) |
| CH (1) | CH675359A5 (en]) |
| DE (1) | DE3815581A1 (en]) |
| DK (1) | DK250088A (en]) |
| FR (1) | FR2614790B1 (en]) |
| GB (2) | GB8710780D0 (en]) |
| IN (1) | IN169811B (en]) |
| IT (1) | IT1217446B (en]) |
| LU (1) | LU87210A1 (en]) |
| MY (1) | MY103079A (en]) |
| NL (1) | NL8801125A (en]) |
| NZ (1) | NZ224363A (en]) |
| OA (1) | OA08843A (en]) |
| SE (1) | SE8801710L (en]) |
| ZA (1) | ZA882963B (en]) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2657018A1 (fr) * | 1990-01-12 | 1991-07-19 | Merck Sharp & Dohme | Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation. |
| EP0457950B1 (fr) * | 1990-05-23 | 1993-10-20 | Societe Des Produits Nestle S.A. | Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires |
| GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
| US5444452A (en) * | 1992-07-13 | 1995-08-22 | Matsushita Electric Works, Ltd. | Dual frequency antenna |
| DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
| FR2722410B1 (fr) * | 1994-07-15 | 1996-10-04 | Grinda Jean Robert | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique |
| DE19503993A1 (de) * | 1995-02-08 | 1996-08-14 | Johann Friedrich Dr Med Desaga | Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen |
| RU2135129C1 (ru) * | 1998-11-18 | 1999-08-27 | Ларионов Евгений Викторович | Глазные капли "корнеалон-плюс" |
| KR20030048129A (ko) * | 2000-11-08 | 2003-06-18 | 산텐 세이야꾸 가부시키가이샤 | 파르네실초산을 유효 성분으로 하는 각결막 질환 치료제 |
| CA2572344A1 (en) * | 2004-07-01 | 2006-01-19 | Schepens Eye Research | Compositions and methods for treating eye disorders and conditions |
| US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
| KR101401353B1 (ko) * | 2005-07-01 | 2014-05-29 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 점안약의 형태로 안구 사용을 위한 생리적 보조제 또는의약품의 제조를 위한 ｌ-카르니틴 또는 알카노일ｌ-카르니틴의 용도 |
| DK1905453T3 (da) * | 2005-07-13 | 2012-11-26 | Santen Pharmaceutical Co Ltd | Konserveringsmiddel til øjenbrug |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT269345B (de) * | 1965-07-20 | 1969-03-10 | Merck & Co Inc | Verfahren zur Herstellung einer sterilen, von festen Teilchen freien Zubereitung für die Augenheilkunde |
| US3549747A (en) * | 1968-02-20 | 1970-12-22 | Flow Pharma Inc | Contact lens wetting solution and method of using same |
| GB1340517A (en) * | 1969-12-01 | 1973-12-12 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| GB2020180B (en) * | 1978-05-08 | 1982-08-25 | Nelson Res & Dev | Ophthalmic compositions containingcolchicine or vinblastinr |
| AU527784B2 (en) * | 1978-05-26 | 1983-03-24 | Bang, Hans Olaf Dr. | Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| FR2548021B1 (fr) * | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
| US4616012A (en) * | 1983-11-25 | 1986-10-07 | Schering Corporation | Carboxyalkyl dipeptides as antiglaucoma agents |
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| JPS6344843A (ja) * | 1986-08-13 | 1988-02-25 | Kao Corp | 油中水中油型乳化油脂組成物 |
-
1987
- 1987-05-07 GB GB878710780A patent/GB8710780D0/en active Pending
-
1988
- 1988-04-22 NZ NZ224363A patent/NZ224363A/xx unknown
- 1988-04-26 ZA ZA882963A patent/ZA882963B/xx unknown
- 1988-04-28 IN IN373/DEL/88A patent/IN169811B/en unknown
- 1988-04-29 MY MYPI88000451A patent/MY103079A/en unknown
- 1988-04-29 IT IT8820388A patent/IT1217446B/it active
- 1988-04-29 FR FR888805735A patent/FR2614790B1/fr not_active Expired - Lifetime
- 1988-04-29 NL NL8801125A patent/NL8801125A/nl not_active Application Discontinuation
- 1988-04-29 CH CH1620/88A patent/CH675359A5/fr not_active IP Right Cessation
- 1988-05-03 BE BE8800497A patent/BE1001075A3/fr not_active IP Right Cessation
- 1988-05-03 GB GB8810422A patent/GB2204239B/en not_active Expired - Lifetime
- 1988-05-05 SE SE8801710A patent/SE8801710L/xx not_active Application Discontinuation
- 1988-05-05 OA OA59347A patent/OA08843A/xx unknown
- 1988-05-06 AU AU15678/88A patent/AU1567888A/en not_active Abandoned
- 1988-05-06 US US07/190,761 patent/US4897421A/en not_active Expired - Fee Related
- 1988-05-06 LU LU87210A patent/LU87210A1/fr unknown
- 1988-05-06 DE DE3815581A patent/DE3815581A1/de not_active Withdrawn
- 1988-05-06 KR KR1019880005253A patent/KR880013557A/ko not_active Withdrawn
- 1988-05-06 DK DK250088A patent/DK250088A/da unknown
- 1988-05-06 JP JP63109221A patent/JPS63297323A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IT1217446B (it) | 1990-03-22 |
| US4897421A (en) | 1990-01-30 |
| DK250088A (da) | 1988-11-08 |
| SE8801710D0 (sv) | 1988-05-05 |
| MY103079A (en) | 1993-04-30 |
| KR880013557A (ko) | 1988-12-21 |
| JPS63297323A (ja) | 1988-12-05 |
| SE8801710L (sv) | 1988-11-08 |
| DE3815581A1 (de) | 1988-11-17 |
| IT8820388A0 (it) | 1988-04-29 |
| BE1001075A3 (fr) | 1989-06-27 |
| GB2204239B (en) | 1990-11-28 |
| AU1567888A (en) | 1988-11-10 |
| CH675359A5 (en]) | 1990-09-28 |
| NL8801125A (nl) | 1988-12-01 |
| GB2204239A (en) | 1988-11-09 |
| GB8810422D0 (en) | 1988-06-08 |
| FR2614790B1 (fr) | 1991-05-31 |
| IN169811B (en]) | 1991-12-28 |
| DK250088D0 (da) | 1988-05-06 |
| OA08843A (fr) | 1989-03-31 |
| NZ224363A (en) | 1990-03-27 |
| GB8710780D0 (en) | 1987-06-10 |
| FR2614790A1 (fr) | 1988-11-10 |
| ZA882963B (en) | 1988-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU87210A1 (fr) | Nouvelle composition ophtalmologique | |
| AU616713B2 (en) | Use of fatty acids against cyclosporin side effects | |
| Kay et al. | Stimulation of taurocholic acid synthesis and biliary excretion of lipids | |
| UA64797C2 (uk) | Інгібітори фарнезил білок трансферази як засіб для лікування артропатії | |
| HU229319B1 (en) | Cathartic composition | |
| JPH06501245A (ja) | 高コレステロール血症の治療法 | |
| FR2629716A1 (fr) | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique | |
| SE1350179A1 (sv) | Farmaceutiska sammansättningar och behandlingsförfaranden | |
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| FR2962912A1 (fr) | Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter la maladie d'alzheimer | |
| Gunas et al. | Indicators cell cycle and DNA fragmentation of spleen cells in early terms after thermal burns of skin at the background of introduction 0. 9% NaCl solution | |
| FR2619718A1 (fr) | Nouvelles formes galeniques de beta-2-mimetiques pour administration par voie per- et sublinguale | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FR2962655A1 (fr) | Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire | |
| JPH04505758A (ja) | 即効で増強された解熱応答 | |
| TWI284529B (en) | A composition for lowering triglyceride | |
| FR2487195A1 (fr) | Procede et composition permettant d'abaisser le taux de cholesterol contenu dans le sang | |
| CH651556A5 (en) | Salt of (benzylindazolyl)oxyacetic acid, process for the preparation of this salt and pharmaceutical composition containing this salt | |
| DE69737888T2 (de) | Anti-mhc klasse ii bindungsreagentien zur verwendung bei xenotransplantationen | |
| HOLMES | Drugs affecting lipid synthesis | |
| FR2705569A1 (fr) | Composition pharmaceutique à base d'une imidazolylcarbazolone destinée à l'administration rectale. | |
| TWI323174B (en) | Topical pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation | |
| Druet et al. | Genetic control of mercury-induced immune response in the rat | |
| JP7498475B2 (ja) | 多発性骨髄腫の治療剤 | |
| FR2487675A1 (fr) | Nouvelles compositions pharmaceutiques injectables a base d'une phenothiazine |